Are newer, more expensive pharmacotherapy options associated with superior symptom control compared to less costly agents used in a collaborative practice setting?
Innovative approaches to care may be necessary to provide the most effective symptom management to hospice patients. One approach is prescribing newer pharmacotherapy options with the potential to improve symptom management in hospice. Such therapies are sometimes prescribed outside of Food and Drug Administration indications and are typically more costly than older agents used for the same symptoms. Another approach is the collaborative practice (CP) care model, whereby clinical pharmacists are given prescriptive authority according to evidence-based protocols and algorithms within boundaries approved by a physician. The agents typically included in CP protocols are those with wide therapeutic indices and with substantial evidence to support their use. The purpose of this study was to examine both approaches to management of pain, insomnia, and nausea, comparing symptom scores for those patients who received noncollaborative drug therapies (transdermal fentanyl, zolpidem, and ondansetron) to those who received agents under CP (oral sustained-release opioids, temazepam, and prochlorperazine). The object of the study was to investigate outcomes associated with newer drug therapy options as compared to older agents for the management of pain, insomnia, and nausea. A secondary goal is to compare symptom outcomes for patients receiving pharmaceutical care under CP and non-CP models. The study design was retrospective with a cohort. A total of 50 patients were randomly selected for each cohort of the pain and insomnia study arms. Only 45 patients prescribed oral ondansetron met inclusion criteria for the nausea group; 45 patients prescribed prochlorperazine were randomly selected as the comparator group. Patients were compared on their degree of response to the prescribed therapy. Response was classified as complete, partial, no improvement from baseline, worsened, or unknown. A complete response was defined as the symptom score improving to a 0 of 10, regardless of the previous value documented. A partial response was defined as any improvement in score that did not result in a 0 of 10. No improvement from baseline reflected a lack of overall change in score throughout the series of data points collected. A worsened response was any score found to be higher than the score documented at the time of dispense. The unknown category reflects any set of scores that had an "N/A " documented at the time of medication dispense or when documented for both attempts subsequent to dispensing the medication. A complete response was present in 14 of 50 (28 [corrected] percent) of the patients prescribed oral therapy [corrected] as compared with 12 of 50 (24 [corrected] percent) of those prescribed fentanyl [corrected] (p = .82). Responses defined as partial, no improvement over baseline, worsened, and unknown were also comparable between the two cohorts. A complete response was seen in 26 patients prescribed temazepam (52 percent), whereas only 11 (22 percent) of patients initially prescribed zolpidem achieved the same response (p = .0037). Both groups had a similar distribution of partial, no improvement over baseline, and worsened responses. For the nausea arm of the study, a difference was found in the number of complete responses, favoring prochlorperazine (22 of 45, 48.9 percent for prochlorperazine, 12 of 45, 26.7 percent for ondansetron, p = .0504), as well as an increased number of worse responses seen with ondansetron patients (p = .0513); however, neither difference was statistically significant. Newer pharmacotherapy options for the management of pain, insomnia, and nausea were not found to be superior when compared to older agents prescribed under CP.
Weschules
Douglas J
DJ
excellRx, Inc., Philadelphia, PA, USA.
Maxwell
Terri
T
Reifsnyder
JoAnne
J
Knowlton
Calvin H
CH
D000465:Algorithms; D014151:Anti-Anxiety Agents / Q000008:administration & dosage / Q000191:economics*; D000932:Antiemetics / Q000008:administration & dosage / Q000191:economics*; D015331:Cohort Studies; D004305:Dose-Response Relationship, Drug; D019317:Evidence-Based Medicine; D005260:Female; D005283:Fentanyl / Q000191:economics; D017051:Hospice Care / Q000191:economics* / Q000379:methods; D006801:Humans; D006993:Hypnotics and Sedatives / Q000008:administration & dosage / Q000191:economics*; D008297:Male; D009294:Narcotics / Q000191:economics; D009325:Nausea / Q000188:drug therapy*; D017294:Ondansetron / Q000191:economics; D010146:Pain / Q000188:drug therapy*; D010593:Pharmaceutical Services / Q000458:organization & administration; D011346:Prochlorperazine / Q000191:economics; D011725:Pyridines / Q000191:economics; D012189:Retrospective Studies; D007319:Sleep Initiation and Maintenance Disorders / Q000188:drug therapy*; D015144:Southeastern United States; D013693:Temazepam / Q000191:economics; D000077334:Zolpidem
D014151:Anti-Anxiety Agents; D000932:Antiemetics; D006993:Hypnotics and Sedatives; D009294:Narcotics; D011725:Pyridines; D017294:Ondansetron; D000077334:Zolpidem; D013693:Temazepam; D005283:Fentanyl; D011346:Prochlorperazine